Fundz

Karyopharm Therapeutics Announces Merger with Ayrmid Ltd.

PUBLIC · KPTINov 02, 2026

Acquiring Company

Karyopharm Therapeutics

Acquired Company

Ayrmid Ltd

NewtonHealthcareBiotechnology

Description

On November 2, 2026, Karyopharm Therapeutics Inc. announced its entry into a Restructuring Support Agreement for a merger with Ayrmid Ltd. This transaction will be executed through a Chapter 11 reorganization process, with an expected closure in the first quarter of 2027. The Company is seeking Court approval for bidding procedures to allow other parties to propose competing bids. The merger aims to revitalize Karyopharm's operations following its bankruptcy filing.

Who to call at Karyopharm Therapeutics, and when

When Karyopharm Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Karyopharm Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Karyopharm Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Karyopharm Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Karyopharm Therapeutics

Location

85 WELLS AVENUE

Newton, Massachusetts, United States

About

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Karyopharm Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Kristin
Likely contact at this company
••••••••@••••••••

See Kristin's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Karyopharm Therapeutics's next move

Learn about Strategic plan

Frequently asked

Who acquired Ayrmid Ltd?

Ayrmid Ltd was acquired by Karyopharm Therapeutics, based in Newton. The deal was reported on November 2, 2026. Karyopharm Therapeutics Inc. Karyopharm Therapeutics is publicly traded (KPTI) and operates in Healthcare.

When did Karyopharm Therapeutics acquire Ayrmid Ltd?

Karyopharm Therapeutics's acquisition of Ayrmid Ltd was reported on November 2, 2026. On November 2, 2026, Karyopharm Therapeutics Inc. announced its entry into a Restructuring Support Agreement for a merger with Ayrmid Ltd. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Ayrmid Ltd do?

Ayrmid Ltd is involved in investments focusing on the biopharmaceutical industry. They aim to enhance the capabilities of acquired companies through strategic funding. Their current proposal includes a cash offer for bluebird bio to facilitate growth. It is privately held, operating in Biotechnology.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.